Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Sucampo Pharmaceuticals, Inc. 

4733 Bethesda Avenue
Suite 450
Bethesda  Maryland  20814  U.S.A.
Phone: 301-961-3400 Fax: 301-961-3440



Start Up

 Company News
Sucampo Pharmaceuticals, Inc. (SCMP), Takeda (TKPYY) Forge $55 Million Deal For Amitiza® 10/22/2014 6:13:13 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Release: Clinical Data For AMITIZA® Lubiprostone To Be Presented At The American College of Gastroenterology 2014 Annual Scientific Meeting 10/13/2014 7:52:05 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Announces Settlement Agreement That Resolves Patent Litigation In U.S. Related To AMITIZA 10/10/2014 7:20:26 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Announces Departure Of Chief Financial Officer 10/7/2014 7:21:53 AM
Sucampo Pharmaceuticals, Inc. (SCMP) And Takeda Pharmaceutical Co. Ltd. (TKPYY) Launch Direct-To-Consumer Advertising Campaign For AMITIZA ® (Lubiprostone) For Chronic Idiopathic Constipation 9/29/2014 10:30:40 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Announces New Exclusive Global Manufacturing And Supply Agreement For Lubiprostone 8/22/2014 7:19:57 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Reports Second Quarter 2014 Financial Results and Corporate Update 8/5/2014 7:55:11 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Announces Publication of NICE Recommendation for AMITIZA(R) (Lubiprostone) 7/23/2014 12:48:33 PM
Sucampo Pharmaceuticals, Inc. (SCMP) Announces Second Quarter 2014 Financial Results And Corporate Update Teleconference And Webcast On August 5 7/22/2014 3:11:06 PM
Sucampo Pharmaceuticals, Inc. (SCMP) Release: Swissmedic Approves AMITIZA® (Lubiprostone) For The Treatment Of Opioid-Induced Constipation 7/8/2014 6:19:12 AM